GLP1R and metabolic dysfunction-associated steatotic liver disease: Nahra et al. highlighted the potential role of cotadutide (dual GLP-1 and glucagon receptor agonist) in the reduction in fibrosis scores in patients with MASLD (p = 0.010), while liraglutide did not have the same outcomes regarding liver fibrosis, measured with fibrosis-4 (FIB-4) index and “non-alcoholic fatty liver disease” NAFLD fibrosis score (NFS) [170].